Banner
HomeFocus → Pharma Execs Dig in for a Fight Against Outraged Senators

Pharma Execs Dig in for a Fight Against Outraged Senators Print E-mail
Written by Emmarie Huetteman, Jay Hancock | KHN   
Wednesday, 27 February 2019 00:00
 
Senators got their first opportunity Tuesday to prod drugmakers about the wallet-emptying prices they charge for prescription drugs. Almost in unison, the executives expressed support for eliminating rebates that flow to industry middlemen instead of patients; for increasing transparency about how they set prices; for shifting to a more value-based pricing system, in which outcomes are rewarded. Together they demurred when asked to commit to lowering list prices on drugs like insulin and the blockbuster rheumatoid arthritis drug Humira. The drugmakers - AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi - appeared before the Senate Finance Committee as lawmakers mull how to best control rising drug prices. 
 

Last Updated on Monday, 01 April 2019 15:57
 


Banner
Website design, development, and hosting provided by
Netphiles